阿布昔替尼片的适应症

Abxitinib tablets are an oral Janus kinase (JAK) inhibitor developed by Pfizer Pharmaceuticals of the United States and have been approved for marketing in many countries around the world. The drug effectively blocks inflammatory signaling pathways by selectively inhibiting JAK1 activity and is mainly used to treat immune-mediated diseases such as moderate to severe atopic dermatitis. In April 2022, abuxitinib was approved for marketing in China and included in the medical insurance directory, providing patients with new treatment options.

Indications of Abxitinib Tablets

As a targeted therapy drug, its indications are clear and it mainly targets specific types of immune-mediated diseases.

Main indications

The main indication of Abxitinib tablets is moderate to severe atopic dermatitis. Clinical studies have confirmed that the drug can significantly improve the skin symptoms and quality of life of patients with atopic dermatitis.

Applicable people

This drug is suitable for adolescents and adult patients aged 12 years and above. For children under 12 years old, its safety and effectiveness have not yet been determined, so use it with caution.

Treatment Features

Abxitinib tablets are administered orally and are easy to use. They can be used alone or in combination with topical glucocorticoids, providing patients with flexible treatment options.

Abxitinib tablets have clear indications and are mainly targeted at patients with moderate to severe atopic dermatitis. Its targeted treatment characteristics bring new hope to such patients.

Efficacy and role of Abxitinib tablets

Abxitinib tablets exert therapeutic effects through a unique pharmacological mechanism and have significant clinical efficacy.

Mechanism of action

Abxitinib is a selective JAK1 inhibitor that reduces the production of pro-inflammatory cytokines by blocking the JAK-STAT signaling pathway, thereby alleviating inflammatory reactions and immune abnormalities.

Clinical efficacy

Clinical trials have shown that abixitinib can significantly improve the itching symptoms, skin lesion area and severity of patients with atopic dermatitis, and most patients can observe significant effects within 12 weeks of treatment.

Dose-effect relationship

The conventional recommended dose is 100 mg once a day, which can be increased to 200 mg once a day for those with poor efficacy. Some patients can achieve sustained improvement by switching to a maintenance dose after initial high-dose treatment for 12 weeks.

The efficacy of Abxitinib tablets stems from its precise mechanism of action. Clinical studies have confirmed that it has a significant therapeutic effect on atopic dermatitis, providing patients with a new treatment option.

Contraindications of Abxitinib Tablets

Although Abxitinib Tablets are highly effective, they need to be contraindicated or used with caution in certain circumstances.

Absolute contraindications

This drug is contraindicated in patients with active severe infections, active tuberculosis, and active hepatitis B or C. It should also be avoided in patients with severe liver and kidney damage.

Relative contraindications

Patients with a history of thrombosis, high risk of cardiovascular disease, and a history of malignant tumors should use it with caution. Elderly patients and smokers need to strengthen monitoring when taking the drug.

Restrictions for special groups

Pregnant women, lactating women and children under 12 years old are not recommended for use. Patients with CYP2C19 slow metabolizers need to adjust the dosage to avoid drug accumulation.

The contraindications of Abxitinib tablets involve infection, liver and kidney function, special groups, etc. Patients should fully evaluate the risks and benefits before taking the drug and strictly follow the doctor's instructions.